

An effective HIV vaccine will help to end the AIDS epidemic in the U.S. while reducing the cost of treatment programs domestically and overseas.

HIV vaccine technology developed with support from the U.S. government is revolutionizing design of new vaccines for other diseases **directly affecting the U.S. population**, such as pandemic flu and respiratory syncytial virus.

An HIV vaccine will bolster **U.S. national security** by restoring stable economies and social structures in low- and middle-income countries hardest hit by AIDS.

HIV-focused scientific and public health capacity in Africa and India built with U.S. support is helping these countries strengthen their health care systems. This capacity will also help **protect the U.S.** from emerging infectious disease threats by controlling outbreaks before they spread widely.

IAVI's Vision: A World Without AIDS

IAVI is dedicated to developing vaccines to prevent HIV/AIDS.



A vaccine is the world's best hope to end HIV/AIDS.

IAVI and its partners are taking innovative vaccine technologies today from the lab bench into human clinical trials.

- Despite impressive advances in HIV treatment and prevention, more than 17 million HIV-infected people still lack access to antiretroviral therapy. We remain far from the targets needed to realize the benefits of “treatment as prevention.”
- While treatment saves lives, patients—and payers—must make a lifelong commitment to maintaining therapy. The long-term costs of treatment programs will grow to unsustainable levels unless we implement effective, long-lasting prevention products.
- HIV infection rates remains unacceptably high. A population “bulge” among young people at very high risk could drive adolescent HIV infection rates from 250,000 in 2015 to nearly 400,000 annually by 2030 if progress in youth outreach stalls.
- Resistance to widely used HIV drugs is emerging and risks compromising the success of treatment efforts. Most new infections now take place in groups not effectively reached by current programs.
- Treatment alone has never ended an epidemic. Only vaccines have succeeded. Ending AIDS will also depend on a vaccine.

With each year that passes, another 1.8 million people are infected with HIV. **The need for a vaccine is as urgent than ever.**

U.S. government support continues to drive HIV vaccine science.

- IAVI's network **fills gaps** by bringing together cutting-edge U.S.-based virology and immunology expertise with local scientists who work directly with at-risk communities – fueling major scientific advances while ensuring products will be affordable, adopted, and effective.
- IAVI's efforts to **build capable clinical research centers** in low- and middle-income countries helps inform rational policies, accelerates those countries' decision-making, and **helps protect** those countries – and the U.S. – from emerging infectious diseases such as Zika and Ebola.
- Community engagement by IAVI and its partners **builds local capacity** while reaching at-risk populations. Engaging these communities will be essential to achieving PEPFAR's goals for HIV treatment and prevention programs.
- IAVI's commitment to building a cadre of outstanding scientific leaders and world-class research capabilities in Africa furthers PEPFAR objectives to **increase country leadership** and **decreases future reliance on foreign aid**.
- IAVI **supports fellow HIV researchers** in the U.S. and around the world by distributing essential samples and reagents to numerous investigators.



The field could not have developed so quickly without IAVI's long-term epidemiological studies with thousands of volunteers that showed us the best antibodies to move forward.

Dennis Burton, PhD, The Scripps Research Institute



- U.S. government investment in IAVI's science **produced discoveries of proteins able to block HIV**. Insights into these “broadly neutralizing antibodies” led to the design of HIV vaccine candidates now entering human clinical testing.
- **Pioneering studies by IAVI** and its partners increased understanding of HIV transmission, and **led to breakthroughs** in vaccine design.
- IAVI's Product Development Center **supports the translation into clinical trials** of promising candidates developed by investigators funded by the National Institutes of Health, the Bill & Melinda Gates Foundation, and the European Union.

To learn more about IAVI, ask questions, or discuss ideas, please contact:

Margaret Lidstone
Vice President,
Global Affairs

MLidstone@iavi.org

Phone: 202-569-5500



IAVI gratefully acknowledges the generous support provided by the following major donors

bgC3 LLC | Bill & Melinda Gates Foundation | Buimerc Core Investments Pvt. Ltd. | Broadway Cares/Equity Fights AIDS | The City of New York, Economic Development Corporation | EMMES Corporation | European Union | Foundation for the National Institutes of Health | The Gilead Foundation | GlaxoSmithKline | Google Inc. | Government of Japan | The Hearst Foundations | Irish Aid, Department of Foreign Affairs and Trade | James B. Pendleton Charitable Trust | Korean Women against AIDS | Ministry of Foreign Affairs of Denmark | Ministry of Foreign Affairs of The Netherlands | Ministry of Science & Technology, Government of India | National Institute of Allergy and Infectious Diseases | Norwegian Ministry of Foreign Affairs | Robert Wood Johnson Foundation | The Starr Foundation | U.K. Department for International Development | The U.S. President's Emergency Plan for AIDS Relief through the U.S. Agency for International Development | The World Bank

And many other generous individuals from around the world

As of January 2018

